新辅助化疗AC或TA方案可降低乳腺癌MVD但不影响P-gp、GST-π的表达

AC or TA neoadjuvant chemotherapy may decrease the microvessel density but does not affect the expressions of P-gp and GST-π in breast carcinoma

目的:探讨AC或TA化疗方案前后同一乳腺癌患者的微血管生成、耐药基因表达及其相互关系。方法:选择AC或TA化疗方案对45例确诊为乳腺癌的患者行术前化疗,用免疫组织化学法分别监测化疗前后同一乳腺癌患者的微血管密度(microvessel density,MVD)计数,以及耐药基因P-糖蛋白(P-glycoprotein,P-gp)和胎盘型谷胱甘肽-S-转移酶π(glutathinona-S-transferase π,GST-π)的表达情况。结果:化疗后MVD计数降低,差异有统计学意义(P<0.01);化疗后P-gp与GST-π阳性表达有部分变化,但差异无统计学意义(P>0.05)。化疗前后MVD与P-gp、GST-π的变化无相关性(P>0.05),P-gp与GST-π的变化有显著相关性(P<0.01)。结论:AC或TA方案可降低乳腺癌患者的MVD计数,但不增加P-gp和GST-π的表达,建议新辅助化疗可考虑首选AC或TA方案。

Objective：To investigate the microvessel density and expression of multiple drug resistance （MDR） gene and their relationship in the same patient with breast carcinoma before and after neoadjuvant AC or TA chemotherapy, nethods：AC or TA regimen was selected to perform preoperative chemotherapy in 45 breast cancer patients. Immunohistochemisty （ En vision method） was used to count the microvessel density （MVD） and determine the expressions of P-glycoprotein （P-gp） and glutathinine-S-transferase π （GST-π） of the same patients before and after neoadjuvant chemotherapy. Results：After neoadjuvant chemotherapy the MVD was decreased. The difference was significant （P 〈0.01 ）. The expression levels of P-gp and GST-π partly changed but the difference was not significant （ P 〉 0.05 ）. There was no significant correlation between MVD and the expressions of P-gp and GST-π （ P 〉 0.05 ） before and after neoadjuvant chemotherapy. The expression of P-gp had significant association with GST-π before and after neoadjuvant chemotherapy （ P 〈 0.01 ）. Conclusions： AC or TA neoadjuvant chemotherapy decreases the number of microvessel density but does not affect the expressions of P-gp and GST-π in breast carcinoma. So this study suggests that AC or TA regimen could be considered first for neoadjuvant chemotherapy.